COVID-19 is a contagious infectious disease caused by SARS-CoV-2. Clinical manifestations range from asymptomatic infection to severe pneumonia, respiratory failure, and multi-organ complications.
A 19-month-old girl with influenza A (H1N1)-associated acute necrotizing encephalitis made a complete neurological recovery despite a severity score of 6. Multimodal immunomodulatory therapy including IVIG, corticosteroids, anakinra, and plasma exchange led to rapid decline in blood cytokine levels. The case underscores early recognition and targeted treatment in young children.
The FDA approved Moderna's mFlusiva, the first mRNA-based flu vaccine, for adults 50 and older. Full approval covers ages 50-64; accelerated approval covers 65+. Moderna expects availability later this year, pending CDC recommendation.
A first-in-human T-cell therapy showed lasting benefit in children with DIPG and relapsed CNS tumors, while a preclinical mRNA vaccine reduced neuroblastoma tumor size by 70%. Aneuploidy predicted response to olaparib plus irinotecan.
FDA approved Moderna's mFLUSIVA, the first mRNA-based flu vaccine for adults 50+. It was 27% more effective than standard flu shots in a large trial. The approval came after earlier FDA pushback.
Roche stock trades steadily as group sales reach the mid-CHF 60 billion range. Q1 2025 revenue edged higher, and 2025 guidance points to low to mid single digit sales growth.
Moderna posted a narrower-than-expected Q2 loss, with mFLUSIVA awaiting an FDA decision and a Phase 3 norovirus trial missing early success criteria. It reaffirmed 2026 revenue growth and cash guidance.
Ivermectin is being promoted again for unproven uses like cancer and hantavirus, while several states consider making it available over the counter. Experts stress there is no clinical evidence for these uses and warn of serious side effects. Prescriptions among cancer patients have more than doubled.
Meta-analysis of 24 trials found chemoimmunotherapy improved survival in PD-L1-high advanced NSCLC. PPIs and antibiotics were linked to worse durvalumab outcomes, and a chronotherapy trial was retracted.
Insilico Medicine named ISM9528 as its 31st AI-driven preclinical pain candidate, published a target discovery study for a rare sinonasal cancer, and advanced partnerships with MSK and Takeda. The company is also presenting oncology programs at AACR 2026.
Recent studies on mRNA COVID-19 vaccines reveal spike protein and mRNA persistence beyond 3.5 years, no brain changes on MRI in healthy adults, and stress responses in heart cells in vitro.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07766512 |
Five-year Follow-up After Sars-CoV-2 Infection: Prevalence and Evolution of Post-acute Sequalae of COVID-19 (PASC) |
NOT_YET_RECRUITING | |
| NCT07758309 |
Online Games to Help Canadian and U.S. Adults Identify COVID-19 and Vaccine Misinformation: Three Sequential Randomized Studies |
COMPLETED | NA |
| NCT07758296 |
An Online Game to Help Canadian Adults Identify COVID-19 Vaccine Misinformation With One-Month Follow-Up |
COMPLETED | NA |
| NCT07746544 |
Study of Secutrelvir in Participants With COVID-19 |
NOT_YET_RECRUITING | PHASE3 |
| NCT07722000 |
Different Treatment Options Used for Post Covid-19 Syndrome |
COMPLETED | NA |
| NCT07720596 |
Molnupiravir and COVID-19 Mortality Reduction in the Omicron Era |
COMPLETED | |
| NCT07719166 |
Treatment and Outcomes in Patients With COVID-19 and Competing Acute Surgical Diseases in Moscow |
COMPLETED | |
| NCT07709637 |
Evaluation of Safety, Tolerance, and Efficacy of Allogeneic LB-DTK-COV19 in Severe Coronavirus Disease 2019 Patients |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT07690943 |
Evaluation of the Safety and Efficacy of Autologous COVID-19 Antigen Specific T Cell in Prolonged SARS-CoV-2 Patients |
COMPLETED | NA |
| NCT07678619 |
Smart Analysis and Decision-Making for Emerging Infectious Diseases |
ENROLLING_BY_INVITATION | NA |
